A popular generic ADHD medication is being recalled nationwide after failing quality tests that could reduce its effectiveness. The US Food and Drug Administration (FDA) announced on 28 October that several lots of lisdexamfetamine dimesylate capsules, the generic version of Vyvanse, are affected.
The recall was prompted by failed dissolution testing, according to the California State Board of Pharmacy. Dissolution is crucial for the drug to be absorbed and have a physiological effect; the impacted capsules may not deliver an optimal level of medicine, potentially affecting therapeutic efficacy.
Officials stated that taking the recalled medication does not pose a health risk, but patients may not receive a full dose. The recall includes multiple dosages: 10mg, 20mg, 30mg, 40mg, 50mg, 60mg, and 70mg pills. A full list of affected bottle codes is available online.
Lisdexamfetamine dimesylate is widely used to treat attention-deficit/hyperactivity disorder (ADHD), a condition characterised by restlessness, concentration difficulties, and impulsivity. In 2023, over nine million prescriptions were written for the drug in the US, according to Newsweek.
The medication was shipped by Sun Pharmaceutical Industries between 1 May and 13 November 2024, with an expiration date of 2026. Patients who have the recalled medicine are advised to contact their doctor or pharmacy for a replacement or refund.
